TuesdayMay 04, 2021 2:24 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales 

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH The approvals XPhyto…

Continue Reading

TuesdayMay 04, 2021 11:44 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders

Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas Tryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp's psilocybin product Following a year in which a global pandemic led to heightened concerns about individuals’ mental well-being while navigating the health emergency’s effects on society (https://ibn.fm/YGqDb), proponents of psychedelic medicine development programs gained stronger allies in…

Continue Reading

MondayMay 03, 2021 3:00 pm

Scientists Criticize Drug War at Psychedelics Event Hosted by Federal Health Agency

Last week, a federal health agency begun a speaker series that will be focused on reviewing the science behind psilocybin mushrooms and the therapeutic potential they possess. Experts who aired their views at the inaugural event claimed that federal drug regulations undermined the scientific community’s research objectives and weren’t in line with what the voters wanted. The event is being hosted by the National Cancer Institute, under the National Institutes of Health (“NIH”). The institute notes that it has some clinical trials looking into the use of psilocybin as a treatment of cancer-related depression, with others exploring the psychedelic’s potential…

Continue Reading

MondayMay 03, 2021 12:57 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Makes Headway into Canadian Cannabis Vape Market with 25,000 Unit Production Run

Production underway for 25,000 vape cartridges using PULL full spectrum oil formulations, including Super Lemon Haze, Grand Daddy Purple and Girl Scout Cookies/GSK Company estimates retail sales revenue for this production run will be approximately $750,000 60% of respondents in StatCan’s Canadian 2020 Cannabis Survey that used vaporizer for cannabis in the last 12 months used oil/extracts “Cannabis 2.0,” the colloquial term for legalization of cannabis derivatives in Canada late in 2019, represented the outset of new trends in how people consume cannabis products with the accessibility of goods like drinks and vape products. While some companies have devoted considerable…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000